(2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism Nahra R, et al
If you need support, speak to your healthcare provider to see if physical therapy or nutrition counseling is right for you
Lower risk of hospitalisation for heart failure, kidney disease and death with sodium glucose co-transporter-2 compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care
#PharmaInsights #Retatrutide #Obesity #GLP1 #GIP #Glucagon #ObesityMedicine #ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #PharmaceuticalMarketing To view or add a comment, sign in Hengrui and Kaileras late-stage success with an oral GLP-1 signals mounting competition in the already crowded obesity therapeutics race, but safety signals may dictate who truly leads this market
This means people start at the lowest dose and its increased over time to keep side effects to a minimum
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test examines your genetic predispositions in GLP-1 receptor (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) pathways
